MedPath
HSA Approval

ANTIPAR FILM COATED TABLET 100 mg/25 mg/200 mg

SIN16956P

ANTIPAR FILM COATED TABLET 100 mg/25 mg/200 mg

ANTIPAR FILM COATED TABLET 100 mg/25 mg/200 mg

February 20, 2024

GOLDPLUS UNIVERSAL PTE LTD

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantGOLDPLUS UNIVERSAL PTE LTD

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

TABLET, FILM COATED

ORAL

Medical Information

N04BA03

levodopa, decarboxylase inhibitor and COMT inhibitor

Manufacturer Information

GOLDPLUS UNIVERSAL PTE LTD

İlko İlaç Sanayi ve Ticaret A. Ş.

Active Ingredients

Carbidopa Monohydrate eqv Carbidopa

25mg

Carbidopa

Entacapone

200.000mg

Entacapone

Levodopa

100.000mg

Levodopa

Documents

Package Inserts

Antipar Tabelt PI.pdf

Approved: February 20, 2024

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

ANTIPAR FILM COATED TABLET 100 mg/25 mg/200 mg - HSA Approval | MedPath